Zoekresultaten - Portaal voor medische datamodellen (MDM-portaal)

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Week 28 - 12-Lead ECG; Ocular Medical Conditions; ETDRS Refraction; ETDRS Visual Acuity; Intraocular Pressure Exam; External Ocular Exam; Eye Lid and Lash Exam

- 06-03-20 - 1 Formulier, 12 Itemgroepen, 60 Data-elementen, 1 Taal

Itemgroepen: Administrative, 12-Lead ECG, Ocular medical conditions, ETDRS Refraction , ETDRS Visual Acuity , Intraocular Pressure Exam , External Ocular Exam , Pupil Exam - Right Eye , Pupil Exam - Left Eye , Motility Exam , Confrontation Visual Field , Eye Lid and Lash Exam

Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Effect of GSK958108 on ejaculatory latency time (ELT); NCT00861484 - Follow-up

- 06-06-20 - 1 Formulier, 14 Itemgroepen, 167 Data-elementen, 1 Taal

Itemgroepen: Date of visit, Vital signs, 12 lead ECG, Laboratory Procedures, Hematology finding, Laboratory Procedures, Chemistry, Clinical, Laboratory Procedures, Urinalysis, Laboratory Procedures, Hormones, Laboratory Procedures, Free Testosterone Measurement, Laboratory Procedures, Prolactin measurement, Nervous system structure, Evaluation, Ophthalmic examination and evaluation, Blinded Clinical Study, Status, Pregnancy, Information, Conclusion, Clinical Research

Study ID: 111155 Clinical Study ID: 111155 Study Title: A double blind, parallel group, placebo controlled study to evaluate the effect of a single oral dose of GSK958108 on ejaculatory latency time (ELT) in male patients suffering from premature ejaculation. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00861484 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK958108 , Placebo Trade Name: N/A Study Indication: Premature Ejaculation

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Week 4 - Vital Signs; Electronically Transferred Lab Data; Liver event assessment; PK Tissue Sample; 12-Lead ECG

- 26-02-20 - 1 Formulier, 8 Itemgroepen, 30 Data-elementen, 1 Taal

Itemgroepen: Administrative, Vital Signs, First sitting BP reading, Second sitting BP reading , Electronically Transferred Lab Data , Liver event assessment, PK Tissue Sample, 12-Lead ECG

Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Screen - Electronically Transferred Lab Data; 12-LEad ECG; Neovascular AMD history and prior AMD medications

- 11-01-20 - 1 Formulier, 4 Itemgroepen, 34 Data-elementen, 1 Taal

Itemgroepen: Electronically Transferred Lab Data, 12-Lead ECG, Neovascular AMD history and prior AMD medications - Right Eye, Neovascular AMD history and prior AMD medications - Left Eye

Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

12 Lead ECG- Follow-up Pazopanib Macular Degeneration MD1103367 - 12 Lead ECG- Follow-up

- 20-06-18 - 1 Formulier, 1 Itemgroep, 8 Data-elementen, 1 Taal

Itemgroep: 12 Lead ECG; Follow- up

Study part: 12 Lead ECG- Follow-up. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Effect of GSK958108 on ejaculatory latency time (ELT); NCT00861484 - Screen

- 31-05-20 - 1 Formulier, 19 Itemgroepen, 203 Data-elementen, 1 Taal

Itemgroepen: Screening procedure, Enrollment, Date of visit, Demography, Eligibility Determination, Inclusion, Exclusion Criteria, Clinical Trial Subject Unique Identifier, Vital signs, 12 lead ECG, Laboratory Procedures, Hematology finding, Laboratory Procedures, Chemistry, Clinical, Laboratory Procedures, Urinalysis, Laboratory Procedures, Hormones, Laboratory Procedures, Free Testosterone Measurement, Laboratory Procedures, Prolactin measurement, Nervous system structure, Evaluation, Ophthalmic examination and evaluation, Ejaculation, Response Latency, Time, Intravaginal

Study ID: 111155 Clinical Study ID: 111155 Study Title: A double blind, parallel group, placebo controlled study to evaluate the effect of a single oral dose of GSK958108 on ejaculatory latency time (ELT) in male patients suffering from premature ejaculation. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00861484 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK958108 , Placebo Trade Name: N/A Study Indication: Premature Ejaculation

12- Lead ECG, Telemetry, Holter Monitoring Pazopanib Macular Degeneration MD1103367 - 12- Lead ECG, Telemetry, Holter Monitoring

- 27-09-21 - 1 Formulier, 3 Itemgroepen, 18 Data-elementen, 1 Taal

Itemgroepen: 12 Lead ECG, Telemetry, 24 Hour Holter Monitoring

Study part: 12- Lead ECG, Telemetry, Holter Monitoring. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

12- Lead ECG Abnormalities (ECG Abn) Pazopanib Macular Degeneration MD1103367 - 12- Lead ECG Abnormalities (ECG Abn)

- 11-06-18 - 1 Formulier, 1 Itemgroep, 12 Data-elementen, 1 Taal

Itemgroep: 12 Lead ECG abnormalities

Study part: 12- Lead ECG Abnormalities (ECG Abn). A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

ECG Pazopanib Macular Degeneration MD1103367 - ECG

- 10-06-18 - 1 Formulier, 2 Itemgroepen, 11 Data-elementen, 1 Taal

Itemgroepen: 24 Hour Holter Monitoring, 12 Lead ECG

Study part: ECG. A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Safety of once-daily administration of Fluticasone nasal spray in adults and adolescents with perennial allergic rhinitis GSK 102123 - Nasal and Opthalmic Examination, Vital Signs, ECG - Visit 15

- 18-05-18 - 1 Formulier, 5 Itemgroepen, 58 Data-elementen, 1 Taal

Itemgroepen: Vital Signs, Nasal Examination, Nasal Candidiasis Examination, Ophthalmic Examination, 12-Lead ECG

Study ID: 102123 Clinical Study ID: FFR102123 Study Title: A randomised double-blind placebo controlled parallel group multicentre long term study to evaluate the safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100mcg* for 52 weeks in adult and adolescent subjects with perennial allergic rhinitis. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: FLUTIDE, Allermist, Veramyst, FLUNASE, FLIXOTAIDE, FLUTAIDE, FLIXOVATE, Avamys; Veramyst, Avamys, Allermist Study Indication: Rhinitis, Allergic, Perennial This ODM-file contains Nasal and Ophthalmic Examination, Vital Signs, ECG; Visit 15, Week 52, Day 365+/-2 days.

Safety of once-daily administration of Fluticasone nasal spray in adults and adolescents with perennial allergic rhinitis GSK 102123 - Nasal and Opthalmic Examination, Vital Signs, ECG - Visit 8